The inhibitor GSK872 of the target molecule RIPK3 has the potential to become a new targeted drug for the treatment of AngII induced myocardial hypertrophy, providing a molecular basis and new clinical treatment strategies for targeted prevention and treatment of myocardial hypertrophy, dilated cardiomyopathy, and heart failure. Here, AGT is linked to heart failure.